Mayo Clinic Finds DNA Aptamers for Senescent Cells
SkimNews Take
The discovery of DNA aptamers for senescent cells, resulting from an exhaustive screening process, highlights how high-volume computational or biological assays are becoming essential for identifying novel therapeutic targets.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Mayo Clinic researchers screened >100 trillion random DNA sequences and identified several aptamers that bind selectively to senescent cells in mouse tissue.
- Jim Maher, III said the aptamer approach establishes a principle for distinguishing senescent cells from healthy ones, with potential application to human cells.
- Keenan Pearson, Ph.D. sparked the idea during a casual conversation, linking aptamer work on brain disease to senescent cell detection.
- Sarah Jachim, Ph.D. contributed by discussing aging research, prompting the adaptation of aptamers to target senescent cells.
- Aging Cell published the study on May 15, 2026, describing the aptamer‑based tagging method that could enable precise identification of senescent cells in living tissue.
Why it matters: Biotech firms targeting age‑related diseases gain a >100‑trillion‑sequence‑derived aptamer tool, potentially cutting R&D time and costs, while patients could see faster therapies for aging, cancer, and neurodegeneration.
